Market Brief
Market BriefCompare MarketsTop 5 MarketsGlobal Value DossierPricing & Evidence SimulatorScenario PlannerRegulatory TrackerVantro Match
InsightsEnterprisePricingContact us
Book a 30 min call
Insights

What we learn from the markets we analyse

Market readiness rankings, analysis, and autopsies, written for the teams making the call.

The Index

The 5 most entry-ready markets for medical devices right nowFor a Class II device, the fastest routes belong to the markets that let you build on an approval you already hold.12 August 2026The single requirement that decides entry in 6 large marketsSix large markets, each decided by one specific requirement, and usually not the one companies screen for.12 August 2026

Market Watch

Market Watch: the US put a 100 percent tariff on patented medicinesA 100 percent tariff on imported patented medicines is operative for a first group of companies, and applies to everyone else from 29 September.15 August 2026Market Watch: WHO and the African Medicines Agency signed a reliance frameworkWHO and the African Medicines Agency signed a framework to drive regulatory reliance across the continent.14 August 2026Market Watch: Vietnam opens a reliance route for six regulatorsAn abbreviated assessment route opens for products already approved by one of six named authorities.13 August 2026Market Watch: the UK raised its cost-effectiveness thresholdNICE's cost-effectiveness range moved for the first time in two decades, and the Secretary of State can now direct it.12 August 2026Market Watch: the UK reliance pathway excludes the EUA new GB route recognises US, Canadian and Australian approvals. Not European ones.26 July 2026

Analysis

Launch order has quietly become a pricing decisionUnder most-favored-nation and reference pricing, the order of entry has become a pricing decision.26 August 2026A URL is not a citationPeer review assumed a human made the analytic decisions and could reconstruct them. That assumption no longer holds.19 August 2026The cheapest line in your model is the one nobody ownsTax and customs is the sixth dimension of market entry, and the one almost no assessment measures.12 August 2026Your first launch price is an input to every price that followsExternal reference pricing is a sequencing constraint, not a fact of life.11 August 2026Regulatory reliance is a strategy, not a shortcutThe approval you already hold determines which markets open next.23 July 2026

Autopsies

Distributor lock-in: when the registration is not in your nameThe registration was never in the company's name, and the company only discovered that when it tried to leave.24 August 2026The sequence error: when an early price sets a later oneA price agreed in a small early market travelled, by rule, into every market the company had been saving.21 August 2026Approved but unpaid: when clearance does not convert to revenueThe company optimised for the regulator, then met a second decision maker it had never designed evidence for.17 August 2026Market entry autopsy: the reference-pricing withdrawalA therapy withdrawn from a market that had done nothing wrong.24 July 2026